The filing for US FDA approval of efalizumab [`Xanelim'; Genentech, XOMA] may be delayed

By  

Inpharma, Vol. 1, Iss. 1333, 2002-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

By Bornstein Gadi   Quéva Christophe   Tabrizi Mohammad   Abbema Anne   Chavez Carlos   Wang Ping   Foord Orit   Ahluwalia Kiran   Laing Naomi   Raja Sandhya   Wen Shenghua   Green Larry   Yang Xiaodong   Webster Carl   Stewart Ross   Blakey David  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 561-574

Springer Publishing Company

Access to resources Recommend Favorite

Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

By Castillo Jorge   Milani Cannon   Mendez-Allwood Daniel  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 491-500

Informa Healthcare

Access to resources Recommend Favorite

Anti-CD4 monoclonal antibody/tumour necrosis factor α inhibitors: Cytokine release syndromes, allergy, CD4+ T-cell lymphopenia and maculopapular rash: 8 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1199, 2008-01 ,pp. : 6-7

Adis International

Access to resources Recommend Favorite

Eculizumab: 5G1.1, h5G1.1, Long-Acting Anti-C5 Monoclonal Antibody 5G1-1, Long-Acting Anti-C5 Monoclonal Antibody 5G1.1

By Adis International Limited  

Drugs in R&D, Vol. 8, Iss. 1, 2007-01 ,pp. : 61-68

Adis International

Access to resources Recommend Favorite